Karnataka defers launch of Covid vax drive for people aged 18-44 yrs
By IANS |
Published on
Fri, Apr 30 2021 15:27 IST |
16 Views
Follow the Pediatric vaccine schedule even in coronavirus. Image Source: IANS News
Bengaluru, April 30 : The Karnataka government has deferred the roll-out of the Covid-19 inoculation drive for those in the 18-44 years age group from Saturday.
State s Health Minister, K. Sudhakar told reporters that the new dates for inoculation for this age group (18-44 years) will be announced once the state receives the required quantity of dosage of vaccine to start the drive. I appeal to our people not to crowd in front of any hospital as inoculation drive won t commence from May 1 as it was decided earlier, he said.
Covid-19 vaccine: India govt s expert committee recommends emergency use approval for Sputnik V
thedailystar.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thedailystar.net Daily Mail and Mail on Sunday newspapers.
Dr Reddy Laboratories seeks from DCGI for emergency use authorisation of Sputnik V vaccine | भारत में जल्द मिल सकती है रूसी कोरोना वैक्सीन Sputnik V को इस्तेमाल की मंजूरी, ट्रायल में 91 6 फीसदी असरदार
india.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from india.com Daily Mail and Mail on Sunday newspapers.
‘5 decades of vaccine excellence is paying off’
March 06, 2021
Suchitra Ella, Joint Managing Director of Bharat Biotech×
Bharat Bio’s Suchitra Ella says India will play a key role supplying Covid vaccines to the world
The near-five decades of vaccine manufacturing capability and excellence is paying off with Hyderabad set to play a significant role in the global supply chain of Covid-19 antidotes, said Suchitra Ella, Joint Managing Director of Bharat Biotech, which makes Covaxin.
Speaking at a CII conference on ‘Industry Reset: Summit on strategic manufacturing in digital era’, the Bharat Biotech co-founder said, “What started as an initiative driven by government institutions 4-5 decades ago, with significant participation of Indian research institutions for basic vaccines has now grown to become a big industry with India accounting for 60-65 per cent of global supplies of vaccines and Hyderabad accounting for about 70 per cent of India’s vaccine manufacturin
Covaxin - AAP 5370537724001
Indian pharmaceutical firm Bharat Biotech says an interim analysis of stage-three trials of its COVID-19 vaccine have shown that it has 81-per-cent efficacy in preventing the disease.
The Hyderabad-based pharmaceutical s jab BBV152, or Covaxin, has been indigenously developed with the support of the state-run Indian Council of Medical Research (ICMR).
Covaxin is one of the two vaccines currently being used to inoculate Indians.
The other is AstraZeneca and Oxford University s vaccine, produced locally by the Serum Institute of India under the name Covishield.
Both recieved emergency authorisation from India s drugs controller in January.
Covaxin s authorisation came in for criticism, as unlike Covishield there was no interim data from stage-three clinical trials on humans at the time.